About Marinus
Marinus is committed to improving the lives of patients with seizure disorders through the development of innovative treatment options and by closely collaborating with patients, caregivers and healthcare professionals.
Our lead drug candidate is designed to exhibit anti-epileptic activity by virtue of its GABAA receptor modulating properties and is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Our Mission
At Marinus, we use a strong scientific rationale, determination and expertise to embrace the challenge of developing treatments for seizure disorders. We are committed to patients, health care providers and the epilepsy community as we plan our path forward to providing much needed options for patients.
Our Vision
Our vision is to strengthen the treatment landscape for children and adults afflicted with seizure disorders.